NanoSphere Health Sciences Inc. (NSHS.CN)
CAD 0.09
(70.0%)
CAD 0.09
(70.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.57 Million USD | 14.76% |
| 2022 | 1.37 Million USD | 13.57% |
| 2021 | 1.2 Million USD | -19.95% |
| 2020 | 1.5 Million USD | 20.41% |
| 2019 | 1.25 Million USD | 160.34% |
| 2018 | 481.37 Thousand USD | 187.56% |
| 2017 | 167.4 Thousand USD | -29.21% |
| 2016 | 236.47 Thousand USD | -12.47% |
| 2015 | 270.15 Thousand USD | 17.34% |
| 2014 | 230.22 Thousand USD | -51.25% |
| 2013 | 472.24 Thousand USD | -6.27% |
| 2012 | 503.85 Thousand USD | 83.44% |
| 2011 | 274.66 Thousand USD | 231.65% |
| 2010 | 82.81 Thousand USD | 446.03% |
| 2009 | 15.16 Thousand USD | -92.25% |
| 2008 | 195.61 Thousand USD | -85.97% |
| 2007 | 1.39 Million USD | 12799.33% |
| 2006 | 10.8 Thousand USD | 93.06% |
| 2005 | 5596.69 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.59 Million USD | 1.31% |
| 2024 Q2 | 1.66 Million USD | 4.22% |
| 2023 Q3 | 1.32 Million USD | -10.91% |
| 2023 Q2 | 1.49 Million USD | 6.21% |
| 2023 Q1 | 1.4 Million USD | 2.32% |
| 2023 Q4 | 1.57 Million USD | 18.53% |
| 2023 FY | 1.57 Million USD | 14.76% |
| 2022 Q4 | 1.37 Million USD | 7.26% |
| 2022 Q3 | 1.27 Million USD | -2.18% |
| 2022 Q1 | 1.27 Million USD | 5.88% |
| 2022 Q2 | 1.3 Million USD | 2.23% |
| 2022 FY | 1.37 Million USD | 13.57% |
| 2021 Q1 | 1.55 Million USD | 2.96% |
| 2021 FY | 1.2 Million USD | -19.95% |
| 2021 Q3 | 1.15 Million USD | -30.45% |
| 2021 Q4 | 1.2 Million USD | 4.23% |
| 2021 Q2 | 1.66 Million USD | 7.25% |
| 2020 Q1 | 1.33 Million USD | 6.71% |
| 2020 Q4 | 1.5 Million USD | 7.45% |
| 2020 Q3 | 1.4 Million USD | 2.66% |
| 2020 Q2 | 1.36 Million USD | 2.29% |
| 2020 FY | 1.5 Million USD | 20.41% |
| 2019 Q2 | 671.82 Thousand USD | 32.67% |
| 2019 FY | 1.25 Million USD | 160.34% |
| 2019 Q1 | 506.37 Thousand USD | 5.19% |
| 2019 Q4 | 1.25 Million USD | 22.19% |
| 2019 Q3 | 1.02 Million USD | 52.66% |
| 2018 Q4 | 481.37 Thousand USD | -36.18% |
| 2018 Q2 | 69.22 Thousand USD | 16.91% |
| 2018 Q1 | 59.21 Thousand USD | -64.63% |
| 2018 Q3 | 754.28 Thousand USD | 989.68% |
| 2018 FY | 481.37 Thousand USD | 187.56% |
| 2017 Q1 | 181.09 Thousand USD | -23.42% |
| 2017 Q2 | 63.43 Thousand USD | -64.97% |
| 2017 FY | 167.4 Thousand USD | -29.21% |
| 2017 Q3 | 103.74 Thousand USD | 63.53% |
| 2017 Q4 | 167.4 Thousand USD | 61.36% |
| 2016 FY | 236.47 Thousand USD | -12.47% |
| 2016 Q3 | 191.37 Thousand USD | -32.87% |
| 2016 Q4 | 236.47 Thousand USD | 23.57% |
| 2016 Q1 | 281.38 Thousand USD | 4.16% |
| 2016 Q2 | 285.09 Thousand USD | 1.32% |
| 2015 FY | 270.15 Thousand USD | 17.34% |
| 2015 Q1 | 249.62 Thousand USD | 8.43% |
| 2015 Q2 | 255.89 Thousand USD | 2.51% |
| 2015 Q4 | 270.15 Thousand USD | 13.84% |
| 2015 Q3 | 237.3 Thousand USD | -7.27% |
| 2014 FY | 230.22 Thousand USD | -51.25% |
| 2014 Q1 | 503.08 Thousand USD | 6.53% |
| 2014 Q4 | 230.22 Thousand USD | 15.2% |
| 2014 Q3 | 199.84 Thousand USD | -65.21% |
| 2014 Q2 | 574.36 Thousand USD | 14.17% |
| 2013 FY | 472.24 Thousand USD | -6.27% |
| 2013 Q4 | 472.24 Thousand USD | 46.77% |
| 2013 Q3 | 321.75 Thousand USD | 28.29% |
| 2013 Q2 | 250.8 Thousand USD | -26.89% |
| 2013 Q1 | 343.07 Thousand USD | -31.91% |
| 2012 Q4 | 503.85 Thousand USD | 88.74% |
| 2012 Q1 | 205.58 Thousand USD | -25.15% |
| 2012 FY | 503.85 Thousand USD | 83.44% |
| 2012 Q2 | 247.05 Thousand USD | 20.17% |
| 2012 Q3 | 266.96 Thousand USD | 8.06% |
| 2011 Q4 | 274.66 Thousand USD | 56.03% |
| 2011 FY | 274.66 Thousand USD | 231.65% |
| 2011 Q3 | 176.02 Thousand USD | 30.98% |
| 2011 Q2 | 134.39 Thousand USD | 60.37% |
| 2011 Q1 | 83.8 Thousand USD | 1.19% |
| 2010 Q2 | 12.93 Thousand USD | -42.64% |
| 2010 FY | 82.81 Thousand USD | 446.03% |
| 2010 Q4 | 82.81 Thousand USD | 338.09% |
| 2010 Q1 | 22.55 Thousand USD | 48.74% |
| 2010 Q3 | 18.9 Thousand USD | 46.1% |
| 2009 Q2 | 169.04 Thousand USD | 0.74% |
| 2009 Q4 | 15.16 Thousand USD | -91.43% |
| 2009 FY | 15.16 Thousand USD | -92.25% |
| 2009 Q1 | 167.79 Thousand USD | -14.22% |
| 2009 Q3 | 177.02 Thousand USD | 4.72% |
| 2008 Q1 | 951.34 Thousand USD | -31.74% |
| 2008 Q4 | 195.61 Thousand USD | -79.35% |
| 2008 Q2 | 1.01 Million USD | 6.99% |
| 2008 Q3 | 947.32 Thousand USD | -6.93% |
| 2008 FY | 195.61 Thousand USD | -85.97% |
| 2007 Q3 | 550.2 Thousand USD | -35.33% |
| 2007 FY | 1.39 Million USD | 12799.33% |
| 2007 Q4 | 1.39 Million USD | 153.32% |
| 2007 Q2 | 850.82 Thousand USD | 988.11% |
| 2007 Q1 | 78.19 Thousand USD | 623.67% |
| 2006 Q4 | 10.8 Thousand USD | 427.31% |
| 2006 Q3 | 2049.08 USD | -1.93% |
| 2006 Q2 | 2089.39 USD | -80.24% |
| 2006 FY | 10.8 Thousand USD | 93.06% |
| 2006 Q1 | 10.57 Thousand USD | 88.9% |
| 2005 Q3 | 32.68 Thousand USD | 0.0% |
| 2005 FY | 5596.69 USD | 0.0% |
| 2005 Q4 | 5596.69 USD | -82.88% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 2.71 Million CAD | 42.111% |
| Asep Medical Holdings Inc | 3.05 Million CAD | 48.411% |
| BetterLife Pharma Inc. | 8.02 Million CAD | 80.37% |
| BioVaxys Technology Corp. | 3.48 Million CAD | 54.83% |
| ChitogenX Inc. | 6.71 Million CAD | 76.543% |
| Rapid Dose Therapeutics Corp. | 5.04 Million CAD | 68.781% |
| Defence Therapeutics Inc. | 4.06 Million CAD | 61.24% |
| Entheon Biomedical Corp. | 85.32 Thousand CAD | -1745.197% |
| Gemina Laboratories Ltd. | 3.04 Million CAD | 48.235% |
| Glow Lifetech Corp. | 2.34 Million CAD | 32.893% |
| Lexston Life Sciences Corp. | 39.86 Thousand CAD | -3849.016% |
| Pharmala Biotech Holdings Inc. | 1.02 Million CAD | -53.003% |
| Doseology Sciences Inc. | 82.49 Thousand CAD | -1808.589% |
| MYND Life Sciences Inc. | 5.77 Million CAD | 72.736% |
| Nova Mentis Life Science Corp. | 841.66 Thousand CAD | -87.062% |
| PharmaTher Holdings Ltd. | 252.9 Thousand CAD | -522.549% |
| PreveCeutical Medical Inc. | 5.95 Million CAD | 73.582% |
| Telescope Innovations Corp. | 1.35 Million CAD | -16.536% |